Shilpa Medicare Ltd., formerly widely referred to as Shilpa Antibiotics was formally created and deployed as a legal entity as a private limited company in Nov.'87 and has been promoted by Vishnukant C Bhutada and his associates.The company produces trimethoprim, an anti-biotic bulk drug. It also manufactures the product for other reputed companies like Eskayef, Bombay Drugs & Pharmas, Bombay Drug House, US Vitamins, Sandoz India, etc, for their export commitments.

Circa 1992, the company installed production facilities to manufacture sodium methoxide.

SAL is the recipient of the World Health Organisation - Good Manufacturing Practices (GMP) certificate. It exports its products to hard-currency areas. The company manufactures 1-methyl, amino-1-methyl, thio-2-nitro ethane, a drug intermediate used in the manufacture of ranitidine, an anti-ulcer drug.

The company proposes to embark upon an expansion project which involves the addition of one more bulk drug to its existing product range -- norfloxacin -- and expand the production capacity of the existing products of the company -- sodium methoxide and trimethoprim.